glucagon-like-peptide-1-(7-36) and Weight-Gain

glucagon-like-peptide-1-(7-36) has been researched along with Weight-Gain* in 1 studies

Other Studies

1 other study(ies) available for glucagon-like-peptide-1-(7-36) and Weight-Gain

ArticleYear
S 23521 decreases food intake and body weight gain in diet-induced obese rats.
    Obesity research, 2004, Volume: 12, Issue:10

    To investigate the effect of S 23521, a new glucagon-like peptide-1-(7-36) amide analogue, on food intake and body weight gain in obese rats, as well as on gene expression of several proteins involved in energy homeostasis.. Lean and diet-induced obese rats were treated with either S 23521 or vehicle. S 23521 was given either intraperitoneally (10 or 100 microg/kg) or subcutaneously (100 microg/kg) for 14 and 20 days, respectively. Because the low-dose treatment did not affect food intake and body weight, the subcutaneous treatment at high dose was selected to test the effect on selected end-points.. Treated obese rats significantly decreased their cumulative energy intake in relation to vehicle-treated counterparts (3401 +/- 65 vs. 3898 +/- 72 kcal/kg per 20 days; p < 0.05). Moreover, their body weight gain was reduced by 110%, adiposity was reduced by 20%, and plasma triglyceride levels were reduced by 38%. The treatment also improved glucose tolerance and insulin sensitivity of obese rats. Regarding gene expression, no changes in uncoupling protein-1, uncoupling protein-3, leptin, resistin, and peroxisome proliferator-activated receptor (PPAR)-gamma were observed.. S 23521 is an effective glucagon-like peptide-1-(7-36) amide analogue, which induced a decrease in energy intake, body weight, and adiposity in a rat model of diet-induced obesity. In addition, the treatment also improved glucose tolerance and insulin sensitivity of obese rats. These results strongly support S 23521 as a putative molecule for the treatment of obesity.

    Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Dose-Response Relationship, Drug; Eating; Energy Metabolism; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Obesity; Peptide Fragments; Random Allocation; Rats; Rats, Wistar; Time Factors; Weight Gain

2004